What Was Approved and What Was Not
Parents of small children with plaque psoriasis have had almost nothing designed for them. That changed at the end of June, though not in quite the way some coverage has suggested.
The FDA approved a supplemental application from Arcutis Biotherapeutics expanding the indication for Zoryve, roflumilast cream 0.3%, to treat plaque psoriasis including skin-fold areas in children down to age 2. The labeled indication now covers adults and pediatric patients 2 years and older.
This is an age expansion rather than a first-ever pediatric treatment. The same cream was already approved for adults and for children down to age 6, with the 6-to-11 indication granted in October 2023. Topical steroids have long been used in children as well.
What is new is narrower and still meaningful. The company describes it as the first once-daily, non-steroidal therapy approved for plaque psoriasis in children as young as 2. That claim concerns the product class and the age floor, not the existence of treatment.
Roflumilast is a phosphodiesterase type 4 inhibitor, meaning it blocks an enzyme inside cells that drives production of inflammatory signals. It is applied once daily, contains no steroid, and carries no labeled restriction on how long it can be used or where on the body.
Psoriasis affects nearly 9 million people in the United States.
Why Steroids Were the Problem
The clinical gap here is specific, and it explains why an age expansion matters more than it might sound.
Topical corticosteroids work, and they remain a mainstay. But psoriasis in young children frequently appears exactly where steroids are least appropriate: the face and the intertriginous areas where skin touches skin, such as the armpits, groin, and folds under the arms and behind the knees. Skin there is thin, and steroid absorption and thinning are greater.
Lisa Swanson, a pediatric dermatologist and an investigator on the trials, put the constraint plainly in the company's announcement, noting that although topical steroids are commonly used in pediatric psoriasis, "they are not recommended on sensitive areas or for long-term, continuous use."
Psoriasis is chronic. A treatment that cannot be used continuously, on the areas most often affected, in the age group least able to tolerate it, leaves families cycling through short courses and gaps.
Leah Howard, chief executive of the National Psoriasis Foundation, said in the same announcement that parents and caregivers of young children "have faced a significant treatment gap for years, with very limited options."
What the Approval Actually Rests On
This is the part worth understanding, because the evidence supporting this age group is not what most people assume a drug approval means.
The expansion was based on a four-week Maximal Usage Systemic Exposure study in children ages 2 to 5 with plaque psoriasis involving at least 2 percent of body surface area. That study was open-label, meaning everyone knew who was getting the drug and there was no placebo group. It assessed pharmacokinetics, safety, tolerability, and what the company describes as exploratory efficacy.
Supporting long-term safety came from an open-label extension study following children ages 2 to 5 for up to 24 weeks. The company reports results generally consistent with the two pivotal placebo-controlled trials conducted in adolescents and adults.
So the efficacy case for 2-to-5-year-olds is largely carried over from older patients. What the pediatric studies established directly is how much drug enters the bloodstream at maximal use, and whether it was tolerated.
That is a legitimate and common regulatory pathway, not a shortcut. But it is a different evidence base than a placebo-controlled trial in the age group, and parents deserve to know which one they are relying on.
Why Pediatric Approvals Lag
The pattern this approval follows is worth explaining, because it is the reason so many drugs children take carry no pediatric labeling at all.
Enrolling young children in placebo-controlled trials is difficult on every axis: recruitment, consent, ethics of assigning placebo in a symptomatic child, and the small size of the eligible population. So sponsors typically establish efficacy in adults first, then run smaller pediatric studies focused on dosing and safety, extrapolating efficacy where the disease and drug behave similarly across ages.
Until that happens, clinicians prescribe off-label, which is legal and often appropriate but leaves them without labeled dosing, without pediatric safety data in the package insert, and sometimes without insurance coverage.
What a labeled pediatric indication changes is concrete. There is now dosing guidance for this age range, pediatric safety data in the label, and a stronger footing for coverage requests.
The label also carries limits. The cream is contraindicated in patients with moderate to severe liver impairment. Reported adverse reactions at 1 percent or more in psoriasis included diarrhea in 3.1 percent, headache in 2.4 percent, insomnia in 1.4 percent, nausea in 1.2 percent, and application site pain, upper respiratory infection, and urinary tract infection each at 1 percent. It is for skin use only.
What Parents Should Ask
The useful conversation is short and specific.
Ask whether your child's psoriasis involves areas where steroids are a poor long-term option, since that is where this product's advantage is clearest. Ask what the plan is if it does not work, and how long to give it before judging. Ask whether the prescriber has used it in this age group.
On cost, ask the office to check coverage before the prescription is written rather than discovering the price at the counter. The manufacturer runs a savings card program, but like most such programs it applies only to commercially insured patients and excludes people whose claims are reimbursed by government programs, so it does nothing for a child on Medicaid or CHIP. The company also offers a patient assistance program for uninsured and underinsured families that is worth asking about directly.
Nobody should stop a working treatment to switch, and no child should start any prescription based on a news article. If a current regimen is controlling the disease without problems, there is no reason to change it.
The confirmed fact is FDA approval of roflumilast cream 0.3% for plaque psoriasis down to age 2, expanded from age 6. Those most affected are families of children under 6 with psoriasis on the face or skin folds. A reasonable next step is a conversation with a dermatologist about whether it fits. The central uncertainty is long-term efficacy in this age group, since the pediatric studies were open-label and short. The next expected developments are payer coverage decisions and real-world use data.
Frequently Asked Questions
Is this the first psoriasis treatment for children? No. The same cream was already approved down to age 6, and topical steroids have long been used. It is described as the first once-daily steroid-free option approved down to age 2.
What did the FDA approve? An expanded indication for roflumilast cream 0.3% covering plaque psoriasis, including skin-fold areas, in patients 2 years and older.
What studies supported it? An open-label four-week study in children ages 2 to 5 measuring drug absorption, safety and tolerability, plus an open-label extension to 24 weeks. Efficacy was largely extrapolated from adult and adolescent trials.
Why does that matter? Because the efficacy evidence in this age group is not from a placebo-controlled trial. That is a common and accepted pathway, but a different evidence base.
Why not just use a steroid cream? Steroids are not recommended for long-term continuous use or on sensitive areas like the face and skin folds, which is where pediatric psoriasis often appears.
What are the side effects? Reported reactions at 1 percent or more included diarrhea, headache, insomnia, nausea, application site pain, upper respiratory infection, and urinary tract infection.
Will insurance cover it? Ask before the prescription is written. The manufacturer's savings card applies only to commercially insured patients and excludes Medicaid and Medicare.
